Ge Long Hui A P P·2025-11-13 03:55Core Viewpoint - BeiGene reported a 41% year-on-year revenue growth to $1.41 billion, with non-GAAP net profit reaching $125 million, exceeding market expectations [1] Group 1: Financial Performance - Revenue increased by 41% to $1.41 billion [1] - Non-GAAP net profit reached $125 million, surpassing market forecasts [1] Group 2: Future Projections - Based on the rapid growth of zanubrutinib sales and effective cost control, the profit forecast for 2025 has been raised by 56% to $331 million [1] - The profit forecast for 2026 remains unchanged [1] Group 3: Ratings and Target Prices - The company maintains an "outperform" rating [1] - Target prices for A-shares, H-shares, and US shares have been adjusted upwards by 3.2%, 3.3%, and 3.7% respectively, to 320 CNY, 250 HKD, and 420 USD [1]